Affiliation:
1. Alexion Pharmaceuticals, Inc., Cheshire, CT
Abstract
Key PointsThis exploratory study describes the effect of eculizumab on multiple physiologic pathways affected by complement dysregulation in aHUS. The results highlight the importance of sustained terminal complement blockade, even in patients with improved clinical laboratory values.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry